Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI322 in Myeloid Tumor
NCT05148442Phase 1Terminated
- Sponsor
- Innovent Biologics
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simridarlimab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and essential thrombocythemia (ET), sponsored by Innovent Biologics. Primary endpoint: Number of treatment related Adverse Events. Started Dec 2021; status: terminated.
02
Drugs
simridarlimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT05148442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148442.